ENDRA Life Sciences (NDRA) Amortization of Deferred Charges (2016)

ENDRA Life Sciences (NDRA) has reported Amortization of Deferred Charges for 9 consecutive years, with $30223.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 4.95% year-over-year to $30223.0; the TTM figure through Mar 2026 stood at $111675.0 (down 26.09% YoY), while the FY2025 annual figure was $113249.0, down 29.08% from the prior year.
• Amortization of Deferred Charges improved to $30223.0 in Q1 2026 per NDRA's latest filing, from $29415.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $42513.0 in Q3 2024 and bottomed at $23434.0 in Q2 2025.
• Historically, Amortization of Deferred Charges has averaged $34851.6 across 5 years, with a median of $35363.0 in 2024.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges surged 90.15% — and 2025, when it slumped 43.44%.
• ENDRA Life Sciences' Amortization of Deferred Charges stood at $35640.0 in 2022, then gained by 10.44% to $39360.0 in 2023, then slipped by 10.15% to $35363.0 in 2024, then retreated by 16.82% to $29415.0 in 2025, then rose by 2.75% to $30223.0 in 2026.
• Business Quant data shows NDRA's Amortization of Deferred Charges at $30223.0 in Q1 2026, $29415.0 in Q4 2025, and $28603.0 in Q3 2025.